RxDoctor Payments Data

Kristin Johnson, MD

Internal Medicine · New Orleans, LANPI 1720037088

Payments from drug & device makers

$9,669in general payments, 2019–2025

Across 25 payments — averaging $386.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$5K
  • Amicus Therapeutics, Inc.$4K
  • Argenx US, Inc.$193
  • UCB, Inc.$125
  • Biohaven Pharmaceutical Holding Company Ltd.$115
  • Tanabe Pharma America, Inc.$71
  • plus $256 from 10 others

What the payments were for

  • Consulting fees$3,64785%
  • Food & beverage$65715%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,669 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$33,971
Medicare patients
129
Services billed
578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin95$147,096
JanuviaSitagliptin Phosphate61$77,439
MounjaroTirzepatide52$64,744
OzempicSemaglutide36$45,762
EliquisApixaban40$40,979
TrulicityDulaglutide27$40,323
XareltoRivaroxaban18$22,462
Breo ElliptaFluticasone/Vilanterol24$15,642
Repatha SureclickEvolocumab13$9,143
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$6,849
Advair HfaFluticasone Propion/Salmeterol13$6,499
SymbicortBudesonide/Formoterol Fumarate28$6,365
PremarinEstrogens, Conjugated13$5,557
Albuterol Sulfate HfaAlbuterol Sulfate115$4,594
Losartan Potassium431$4,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$45,76236 claims
Johnson & JohnsonXarelto$17$22,46218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →